VRPX's logo.
Ticker Symbol: VRPX

Virpax Pharmaceuticals Inc

$4.22 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001708331

Company Profile

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.78
Change: -$0.03 ( -3.86%)
Days Range: $0.75 - $0.82
Beta: 0.22
52wk. High: $1.20
52wk. Low: $0.61
Ytd. Change 26.51%
50 Day Moving Average: $0.79
200 Day Moving Average: $0.84
Shares Outstanding: 11714284

Valuation

Market Cap: 913.7M
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A